← ANALYST RATINGS · TIPRANKS
Embecta Corporation (EMBC): analyst forecast and price target
Analyst consensus
Moderate Sell0 Buy0 Hold1 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $6.27.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $5.50 → $7.00+27.3% | Hold | +11.6% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.50 → $7.00+27.3% | Hold | +11.6% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $5.50 → $6.50+18.2% | Hold | +3.7% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $5.00 → $6.50+30.0% | Hold | +3.7% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $5.50 → $7.00+27.3% | Hold | +11.6% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $6.50+30.0% | Hold | +3.7% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | — | Hold | — | Reiterated | 09.10.26on TipRanks Oct 12 09:45 | −1.7%next day +5.4% · 5 days +12.3% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | — | Sell | — | Reiterated | 10.08.26on TipRanks 09:55 | +12.9%next day −1.9% · 5 days +2.9% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $12.00 → $5.00−58.3% | Hold | −20.3% | Reiterated | 06.05.26on TipRanks May 9 11:05 | −10.1%next day +1.4% · 5 days −13.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Embecta Corporation
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 01.12.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.29 (from $0.28 to $0.31). Last quarter: $0.56.
Sales
Next quarter’s sales estimate — $267M (from $258M to $270M). Last quarter: $272M.
Best top-analyst consensus in the sector · Healthcare
About Embecta Corporation
- CEO: Devdatt Kurdikar
- Employees: 1,850
- 300 Kimball Drive, Parsippany, NJ, 07054, US
- www.embecta.com
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Data from the stock’s TipRanks forecast page, read 259 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗